Clinical Trials Logo

Filter by:
NCT ID: NCT04051242 Terminated - Muscle Loss Clinical Trials

Enhanced Bioscaffold for Volumetric Muscle Loss

MTEC-VML
Start date: February 10, 2020
Phase: N/A
Study type: Interventional

This is a prospective, single center study conducted at the University of Pittsburgh designed to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after soft tissue trauma.

NCT ID: NCT04051229 Terminated - PreDiabetes Clinical Trials

Exercise Training and Metabolic Flexibility in Prediabetes

Start date: October 29, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if a 6-week exercise training program promotes exercise-induced metabolic flexibility, that is, the ability to switch fuel sources for energy, in older prediabetic adults.

NCT ID: NCT04050982 Terminated - Atrial Fibrillation Clinical Trials

Feasibility Study to Improve AF Outcomes Using a Digital Application for CV Risk Reduction

AFCARE
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

The pilot portion of this study is to determine the feasibility of utilizing AF CARE to provide lifestyle modification support to patients with atrial fibrillation (AF). The prospective, RCT portion of this study compare cardiovascular risk factors (CVRF), AF knowledge, AF Symptom Severity and Burden, and QOL between and within the wait list group and the AF CARE group at baseline, 3, 6, and 12 months.

NCT ID: NCT04050969 Terminated - Atrial Fibrillation Clinical Trials

Bariatric Atrial Restoration of Sinus Rhythm

BAROS
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to determine whether bariatric surgery followed by Atrial Fibrillation (AF) catheter ablation is superior to AF catheter ablation alone in the management of atrial fibrillation in patients with morbid obesity.

NCT ID: NCT04049981 Terminated - Clinical trials for Autism Spectrum Disorder

Investigation of Mechanisms of Action in Superpower Glass

Start date: September 4, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The following study aims to understand the mechanism of action at work in a novel artificial intelligence (AI) tool that runs on Google Glass through an Android app to deliver social emotion cues to children with autism during social interactions. This study will examine 2 versions of software on the Google Glass based wearable intervention system. Participants will receive 1 of 2 versions of the software and use the device at home for 4 weeks. This novel device will use a camera, microphone, head motion tracker to analyze the behavior of the subject during interactions with other people. The system is designed to give participants non-interruptive social cues in real-time and will record social responses that can later be used to help aid behavioral therapy. It is hypothesized that both mechanisms under investigation will contribute to social gains in children over the 4 week period of use.

NCT ID: NCT04049617 Terminated - Clinical trials for Advanced Solid Tumors

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors

Start date: August 26, 2019
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to characterize the safety and tolerability of evixapodlin (formerly GS-4224) and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of evixapodlin in participants with advanced solid tumors.

NCT ID: NCT04049578 Terminated - Clinical trials for Autism Spectrum Disorder

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder

Start date: December 19, 2019
Phase: Phase 1
Study type: Interventional

This was a Phase Ib, multicenter, open-label study in children 2-4 years old with autism spectrum disorder (ASD) to investigate the pharmacokinetics, safety, and tolerability of an oral dose of balovaptan once a day (QD). The study was to consists of a 6-week treatment period to evaluate the pharmacokinetics of balovaptan in 2 to 4 year old children followed by an optional extension period of 48 weeks.

NCT ID: NCT04049487 Terminated - Clinical trials for Diastasis Recti and Weakness of the Linea Alba

Impact of Exercise on Diastasis Rectus Abdominus

Start date: October 14, 2019
Phase: N/A
Study type: Interventional

The aim with this research project is to evaluate the success of diastasis recti closure after a 4-week group exercise class that includes: strengthening of each abdominal muscle group, hip strengthening and stabilization, and pelvic floor activation and cueing during exercises. Success will be evaluated by measuring width and depth of linea alba laxity before and after completion of the 4 sessions as well as other outcome measures such as lumbopelvic pain, pain with intercourse, and incontinence. Intervention will be compared to a control group that participates in an exercise program geared toward general health and wellness.

NCT ID: NCT04049266 Terminated - Clinical trials for Wet Macular Degeneration

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

DAZZLE
Start date: September 30, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with treatment-naïve neovascular (wet) age-related macular degeneration (nAMD).

NCT ID: NCT04049097 Terminated - Clinical trials for Inclusion Body Myositis

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Start date: May 20, 2019
Phase: Phase 3
Study type: Interventional

A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)